CX3CL1



CX3CL1

Q1QQ1H2HH2H3HH3G4GG4V5VV5T6TT6K7KK7C8CC8N9NN9I10II10T11TT11C12CC12S13SS13K14KK14M15MM15T16TT16S17SS17K18KK18I19II19P20PP20V21VV21A22AA22L23LL23L24LL24I25II25H26HH26Y27YY27Q28QQ28Q29QQ29N30NN30Q31QQ31A32AA32S33SS33C34CC34G35GG35K36KK36R37RR37A38AA38I39II39I40II40L41LL41E42EE42T43TT43R44RR44Q45QQ45H46HH46R47RR47... and 326 more residue(s)...... and 326 more residue(s)

SMILES None
InChIKey None
Sequence QHHGVTKCNITCSKMTSKIPVALLIHYQQNQASCGKRAIILETRQHRLFCADPKEQWVKDAMQHLDRQAAALTRNGGTFEKQIGEVKPRTTPAAGGMDESVVLEPEATGESSSLEPTPSSQEAQRALGTSPELPTGVTGSSGTRLPPTPKAQDGGPVGTELFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEAPSTQDPSTQASTASSPAPEENAPSEGQRVWGQGQSPRPENSLEREEMGPVPAHTDAFQDWGPGSMAHVSVVPVSSEGTPSREPVASGSWTPKAEEPIHATMDPQRLGVLITPVPDAQAATRRQAVGLLAFLGLLFCLGVAMFTYQSLQGCPRKMAGEMAEGLRYIPRSCGSNSYVLVPV

Chemical Properties

Hydrogen bond acceptors None
Hydrogen bond donors None
Rotatable bonds None
Molecular weight (Da)

Database connections

Structure pdb 4XT3 4XT1 5WB2
Ligand site mutations US28

No bioactivity data available.

CX3CL1

Q1QQ1H2HH2H3HH3G4GG4V5VV5T6TT6K7KK7C8CC8N9NN9I10II10T11TT11C12CC12S13SS13K14KK14M15MM15T16TT16S17SS17K18KK18I19II19P20PP20V21VV21A22AA22L23LL23L24LL24I25II25H26HH26Y27YY27Q28QQ28Q29QQ29N30NN30Q31QQ31A32AA32S33SS33C34CC34G35GG35K36KK36R37RR37A38AA38I39II39I40II40L41LL41E42EE42T43TT43R44RR44Q45QQ45H46HH46R47RR47... and 326 more residue(s)...... and 326 more residue(s)

Drug properties

Molecular type Peptide
Physiological/Surrogate Endogenous
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections

Structure pdb 4XT3 4XT1 5WB2
Ligand site mutations US28

Compound is not listed as a drug.